Biotechnology - Mergers & Acquisitions, Biotie Therapies


Popular Filters

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate


Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal


Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research


Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development


In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top